According to Huaxi Biotech's announcement, the majority shareholder Guoshou Chengda reduced its holdings according to the holdings reduction plan. From November 26, 2025 to January 7, 2026, it reduced its holdings of 284,4591 shares through centralized bidding, accounting for 0.59%; on January 6, 2026, it reduced its holdings of 2008,000 shares through bulk transactions, accounting for a total of 485,2591 shares, accounting for 1.01%. After this change in equity, China Life Insurance Chengda held 24083,913 shares, accounting for about 5.00% of the total share capital. This change will not lead to changes in the controlling shareholders and actual controllers of the company, and the holdings reduction plan has not yet been implemented.

According to Huaxi Biotech's announcement, the majority shareholder Guoshou Chengda reduced its holdings according to the holdings reduction plan. From November 26, 2025 to January 7, 2026, it reduced its holdings of 284,4591 shares through centralized bidding, accounting for 0.59%; on January 6, 2026, it reduced its holdings of 2008,000 shares through bulk transactions, accounting for a total of 485,2591 shares, accounting for 1.01%. After this change in equity, China Life Insurance Chengda held 24083,913 shares, accounting for about 5.00% of the total share capital. This change will not lead to changes in the controlling shareholders and actual controllers of the company, and the holdings reduction plan has not yet been implemented.